Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan™) in patients with B-cell chronic lymphocytic leukemia:: A phase I/II study.

被引：0
|
作者：
Winkler, U
Schulz, HR
Jensen, M
Manzke, O
Rüdiger, T
Müller-Hermelink, KH
Diehl, V
Engert, A
机构：
[1] Univ Cologne, Clin Internal Med 1, Cologne, Germany
[2] Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1396
引用
收藏
页码：312A / 312A
页数：1
相关论文
共 50 条
  • [1] Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab
    Pickartz, T
    Ringel, F
    Wedde, M
    Renz, H
    Klein, A
    von Neuhoff, N
    Dreger, P
    Kreuzer, KA
    Schmidt, CA
    Srock, S
    Schoeler, D
    Schriever, F
    [J]. EXPERIMENTAL HEMATOLOGY, 2001, 29 (12) : 1410 - 1416
  • [2] Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia
    Pantelidou, D
    Tsatalas, C
    Margaritis, D
    Kaloutsi, V
    Spanoudakis, E
    Bourikas, G
    [J]. HEMATOLOGY JOURNAL, 2004, 5 (06) : 546 - 547
  • [3] Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
    Winkler, U
    Jensen, M
    Manzke, O
    Tesch, H
    Bohlen, H
    Diehl, V
    Engert, A
    [J]. BLOOD, 1998, 92 (10) : 285B - 285B
  • [4] Treatment of chronic lymphocytic leukemia (CLL)with the anti-CD20 antibody rituximab.
    Emmerich, B
    Huhn, D
    Peschel, C
    Wilhelm, M
    von Schilling, C
    Bentz, M
    Hallek, M
    Knauf, B
    Kuse, R
    Ho, AD
    [J]. BLOOD, 1999, 94 (10) : 309B - 309B
  • [5] Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
    Coiffier, Bertrand
    Lepretre, Stephane
    Pedersen, Lars Moller
    Gadeberg, Ole
    Fredriksen, Henrik
    van Oers, Marinus H. J.
    Wooldridge, James
    Kloczko, Janusz
    Holowiecki, Jerzy
    Hellmann, Anrzej
    Walewski, Jan
    Flensburg, Mimi
    Petersen, Jorgen
    Robak, Tadeusz
    [J]. BLOOD, 2008, 111 (03) : 1094 - 1100
  • [6] Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Ogura, Michinori
    Hatake, Kiyohiko
    Tobinai, Kensei
    Uchida, Toshiki
    Suzuki, Tatsuya
    Terui, Yasuhito
    Yokoyama, Masahiro
    Maruyama, Dai
    Mori, Masakazu
    Jewell, Roxanne C.
    Katsura, Koichi
    Hotta, Tomomitsu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 466 - 475
  • [7] Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL).
    O'Brien, S
    Freireich, E
    Andreeff, M
    Lerner, S
    Keating, M
    [J]. BLOOD, 1998, 92 (10) : 105A - 105A
  • [8] Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia
    Perz, J
    Topaly, J
    Fruehauf, S
    Hensel, M
    Ho, AD
    [J]. LEUKEMIA & LYMPHOMA, 2002, 43 (01) : 149 - 151
  • [9] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    [J]. ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [10] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    [J]. Arthritis Res Ther, 5
12345